A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen

Infection and Immunity

Volumn 77, Issue 12, 2009, Pages 5509-5518

  Oscherwitz, Jon ^a,b   Yu, Fen ^a   Cease, Kemp B ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; EPITOPE; GLUTAMYLVALYLHISTIDYLALANYLSERYLPHENYLALANYLPHENYLALANYL ASPARTYLISOLEUCYLGLYCYLGLYCYLSERINE; GLYCYLASPARAGINYLALANYLGLUTAMYLVALYLHISTIDYLALANYLSERYLPHENYL ALANYLPHENYLALANYLASPARTYLISOLEUCYLGLYCYLGLYCYLSERINE; HISTIDYLALANYLSERYLPHENYLALANYLPHENYLALANYLASPARTYL ISOLEUCYLGLYCYLGLYCYLSERYLVALYLSERYLALANYLGLYCYLPHENYLALANYLSERYL ASPARAGINYLSERINE; HISTIDYLGLYCYLASPARAGINYLALANYLGLUTAMYLVALYLHISTIDYL ALANYLSERYLPHENYLALANYLPHENYLALANYLASPARTYLISOLEUCYLGLYCYLGLYCYLSERINE; HISTIDYLTHREONYLSERYLGLUTAMYLVALYLHISTIDYLGLYCYLASPARAGINYL ALANYLGLUTAMYLVALYLHISTIDYLALANYLSERYLPHENYLALANYLPHENYLALANYLASPARTIC ACID; MULTIPLE ANTIGENIC PEPTIDE VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; PROTEIN P30; TETANUS TOXIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTHRAX; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BACILLUS ANTHRACIS; CONTROLLED STUDY; FEMALE; HELPER CELL; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RABBIT; T LYMPHOCYTE;

ANIMALS; ANTHRAX VACCINES; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; ANTITOXINS; BACILLUS ANTHRACIS; BACTERIAL TOXINS; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED STRAINS; RABBITS; TETANUS TOXIN; VACCINES, SUBUNIT;

EID: 72449196664     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00899-09     Document Type: Article

References (51)

1. Albrecht, M. T., H. Li, E. D. Williamson, C. S. LeButt, H. C. Flick-Smith, C. P. Quinn, H. Westra, D. Galloway, A. Mateczun, S. Goldman, H. Groen, and L. W. Baillie. 2007. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 75:5425-5433.
2. Amir-Kroll, H., G. Nussbaum, and I. R. Cohen. 2003. Proteins and their derived peptides as carriers in a conjugate vaccine for Streptococcus pneumoniae: self-heat shock protein 60 and tetanus toxoid. J. Immunol. 170:6165-6171. (Pubitemid 36682600)
3. Brookmeyer, R., E. Johnson, and R. Bollinger. 2004. Public health vaccination policies for containing an anthrax outbreak. Nature 432:901-904. (Pubitemid 40037150)
4. Brossier, F., M. Levy, A. Landier, P. Lafaye, and M. Mock. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72:6313-6317.
5. Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45-70.
6. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
7. Fairweather, N. F., V. A. Lyness, D. J. Pickard, G. Allen, and R. O. Thomson. 1986. Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J. Bacteriol. 165:21-27.
8. Fowler, R. A., G. D. Sanders, D. M. Bravata, B. Nouri, J. M. Gastwirth, D. Peterson, A. G. Broker, A. M. Garber, and D. K. Owens. 2005. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann. Intern. Med. 142:601-610.
9. Francis, M. J., G. Z. Hastings, A. D. Syred, B. McGinn, F. Brown, and D. J. Rowlands. 1987. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature 330:168-170.
10. Friguet, B., A. F. Chaffotte, L. Djavadi-Ohaniance, and M. E. Goldberg. 1985. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77:305-319. (Pubitemid 15103678)
11. Gershon, R. K., and W. E. Paul. 1971. Effect of thymus-derived lymphocytes on amount and affinity of anti-hapten antibody. J. Immunol. 106:872-874.
12. Good, M. F., W. L. Maloy, M. N. Lunde, H. Margalit, J. L. Cornette, G. L. Smith, B. Moss, L. H. Miller, and J. A. Berzofsky. 1987. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 235:1059-1062.
13. Gubbins, M. J., J. D. Berry, C. R. Corbett, J. Mogridge, X. Y. Yuan, L. Schmidt, B. Nicolas, A. Kabani, and R. S. Tsang. 2006. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol. 47:436-443.
14. Gubbins, M. J., L. Schmidt, R. S. Tsang, J. D. Berry, A. Kabani, and D. I. Stewart. 2007. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine. J. Immunoassay Immunochem. 28:213-225.
15. Hanson, J. F., S. C. Taft, and A. A. Weiss. 2006. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin. Vaccine Immunol. 13:208-213.
16. Hering, D., W. Thompson, J. Hewetson, S. Little, S. Norris, and J. Pace- Templeton. 2004. Validation of the anthrax lethal toxin neutralization assay. Biologicals 32:17-27. (Pubitemid 38333181)
17. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
18. Klein, J. 1986. Natural history of the major histocompatibility complex. Wiley, New York, NY.
19. Klinman, D. M., H. Xie, S. F. Little, D. Currie, and B. E. Ivins. 2004. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22:2881-2886.
20. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166.
21. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175.
22. Little, S. F., B. E. Ivins, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430.
23. Little, S. F., B. E. Ivins, W. M. Webster, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2006. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24:2530-2536.
24. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
25. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142(Pt. 3):707-715.
26. Liu, T. H., J. Oscherwitz, B. Schnepp, J. Jacobs, F. Yu, K. B. Cease, and P. R. Johnson. 2009. Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors. Mol. Ther. 17:373-379.
27. Maynard, J. A., C. B. Maassen, S. H. Leppla, K. Brasky, J. L. Patterson, B. L. Iverson, and G. Georgiou. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:597-601.
28. Milich, D. R., J. L. Hughes, A. McLachlan, G. B. Thornton, and A. Moriarty. 1988. Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc. Natl. Acad. Sci. USA 85:1610-1614.
29. Mohamed, N., M. Clagett, J. Li, S. Jones, S. Pincus, G. D'Alia, L. Nardone, M. Babin, G. Spitalny, and L. Casey. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73:795-802.
30. O'Hern, P. A., Z. G. Liang, C. S. Bambra, and E. Goldberg. 1997. Colinear synthesis of an antigen-specific B-cell epitope with a 'promiscuous' tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive. Vaccine 15:1761-1766.
31. Oscherwitz, J., F. Yu, J. L. Jacobs, T. H. Liu, P. R. Johnson, and K. B. Cease. 2009. Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen. Infect. Immun. 77:3380-3388.
32. Palker, T. J., T. J. Matthews, A. Langlois, M. E. Tanner, M. E. Martin, R. M. Scearce, J. E. Kim, J. A. Berzofsky, D. P. Bolognesi, and B. F. Haynes. 1989. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J. Immunol. 142:3612-3619.
33. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237-2242.
34. Petkov, P. M., Y. Ding, M. A. Cassell, W. Zhang, G. Wagner, E. E. Sargent, S. Asquith, V. Crew, K. A. Johnson, P. Robinson, V. E. Scott, and M. V. Wiles. 2004. An efficient SNP system for mouse genome scanning and elucidating strain relationships. Genome Res. 14:1806-1811.
35. Pitt, M. L., S. Little, B. E. Ivins, P. Fellows, J. Boles, J. Barth, J. Hewetson, and A. M. Friedlander. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87:304.
36. Pitt, M. L., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
37. Pittman, P. R., S. F. Leitman, J. G. Oro, S. L. Norris, N. M. Marano, M. V. Ranadive, B. S. Sink, and K. T. McKee, Jr. 2005. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin. Diagn. Lab. Immunol. 12:713-721.
38. Rath, S., C. M. Stanley, and M. W. Steward. 1988. An inhibition enzyme immunoassay for estimating relative antibody affinity and affinity heterogeneity. J. Immunol. Methods 106:245-249. (Pubitemid 18054251)
39. Reason, D., J. Liberato, J. Sun, W. Keitel, and J. Zhou. 2009. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect. Immun. 77:2030-2035.
40. Reason, D. C., A. Ullal, J. Liberato, J. Sun, W. Keitel, and J. Zhou. 2008. Domain specificity of the human antibody response to Bacillus anthracis protective antigen. Vaccine 26:4041-4047.
41. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893.
42. Rosovitz, M. J., P. Schuck, M. Varughese, A. P. Chopra, V. Mehra, Y. Singh, L. M. McGinnis, and S. H. Leppla. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278:30936-30944.
43. Semenova, V. A., D. S. Schmidt, T. H. Taylor, Jr., H. Li, E. Steward-Clark, S. D. Soroka, M. M. Ballard, and C. P. Quinn. 2007. Analysis of antiprotective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax. Vaccine 25:1780-1788.
44. Sharma, S., D. Thomas, J. Marlett, M. Manchester, and J. A. Young. 2009. Efficient neutralization of antibody-resistant forms of anthrax toxin by a soluble receptor decoy inhibitor. Antimicrob. Agents Chemother. 53:1210-1212.
45. Valmori, D., A. Pessi, E. Bianchi, and G. Corradin. 1992. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149:717-721.
46. Vitale, L., D. Blanset, I. Lowy, T. O'Neill, J. Goldstein, S. F. Little, G. P. Andrews, G. Dorough, R. K. Taylor, and T. Keler. 2006. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. 74:5840-5847.
47. Wang, C. Y., D. J. Looney, M. L. Li, A. M. Walfield, J. Ye, B. Hosein, J. P. Tam, and F. Wong-Staal. 1991. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 254:285-288.
48. Weiss, S., D. Kobiler, H. Levy, H. Marcus, A. Pass, N. Rothschild, and Z. Altboum. 2006. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74:394-398.
49. Welkos, S., S. Little, A. Friedlander, D. Fritz, and P. Fellows. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147:1677-1685. (Pubitemid 32544833)
50. Xie, H., I. Gursel, B. E. Ivins, M. Singh, D. T. O'Hagan, J. B. Ulmer, and D. M. Klinman. 2005. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73:828-833.
51. Zhang, J., J. Xu, G. Li, D. Dong, X. Song, Q. Guo, J. Zhao, L. Fu, and W. Chen. 2006. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem. Biophys. Res. Commun. 341:1164-1171.